204 related articles for article (PubMed ID: 8487077)
1. The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
Jachimczak P; Bogdahn U; Schneider J; Behl C; Meixensberger J; Apfel R; Dörries R; Schlingensiepen KH; Brysch W
J Neurosurg; 1993 Jun; 78(6):944-51. PubMed ID: 8487077
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides.
Jachimczak P; Hessdörfer B; Fabel-Schulte K; Wismeth C; Brysch W; Schlingensiepen KH; Bauer A; Blesch A; Bogdahn U
Int J Cancer; 1996 Jan; 65(3):332-7. PubMed ID: 8575854
[TBL] [Abstract][Full Text] [Related]
3. Transforming growth factor-beta-mediated regulation of human peripheral blood mononuclear cell proliferation as detected with phosphorothioate antisense oligodeoxynucleotides.
Jachimczak P; Fabel-Schulte K; Hessdörfer B; Brysch W; Schlingensiepen KH; Blesch A; Bogdahn U
Cell Immunol; 1995 Oct; 165(1):125-33. PubMed ID: 7671316
[TBL] [Abstract][Full Text] [Related]
4. In vitro studies of cytokine-mediated interactions between malignant glioma and autologous peripheral blood mononuclear cells.
Jachimczak P; Schwulera U; Bogdahn U
J Neurosurg; 1994 Oct; 81(4):579-86. PubMed ID: 7931592
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of immunosuppressive effects of melanoma-inhibiting activity (MIA) by antisense techniques.
Jachimczak P; Apfel R; Bosserhoff AK; Fabel K; Hau P; Tschertner I; Wise P; Schlingensiepen KH; Schuler-Thurner B; Bogdahn U
Int J Cancer; 2005 Jan; 113(1):88-92. PubMed ID: 15386421
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
7. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
[TBL] [Abstract][Full Text] [Related]
8. Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo.
Ständer M; Naumann U; Dumitrescu L; Heneka M; Löschmann P; Gulbins E; Dichgans J; Weller M
Gene Ther; 1998 Sep; 5(9):1187-94. PubMed ID: 9930319
[TBL] [Abstract][Full Text] [Related]
9. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
10. T cell-mediated cytotoxicity of human gliomas: a tumor necrosis factor-independent mechanism.
Baltuch GH; Villemure JG; McCrea E; Antel JP
Neurosurgery; 1994 Sep; 35(3):450-6; discussion 456. PubMed ID: 7800136
[TBL] [Abstract][Full Text] [Related]
11. Autoinduction of platelet derived growth factor (PDGF) A-chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A-chain mRNA-specific antisense molecules.
Behl C; Bogdahn U; Winkler J; Apfel R; Brysch W; Schlingensiepen KH
Biochem Biophys Res Commun; 1993 Jun; 193(2):744-51. PubMed ID: 8512572
[TBL] [Abstract][Full Text] [Related]
12. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
Smyth MJ; Strobl SL; Young HA; Ortaldo JR; Ochoa AC
J Immunol; 1991 May; 146(10):3289-97. PubMed ID: 1827481
[TBL] [Abstract][Full Text] [Related]
13. [Isolation and expansion of glioma-infiltrating lymphocytes in vitro: an analysis of their surface phenotypes and antitumor activities].
Sawamura Y
Hokkaido Igaku Zasshi; 1991 Nov; 66(6):868-78. PubMed ID: 1783372
[TBL] [Abstract][Full Text] [Related]
14. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain.
Weller M; Fontana A
Brain Res Brain Res Rev; 1995 Sep; 21(2):128-51. PubMed ID: 8866671
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
[TBL] [Abstract][Full Text] [Related]
16. Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
Holladay FP; Lopez G; De M; Morantz RA; Wood GW
Neurosurgery; 1992 Apr; 30(4):499-504; discussion 504-5. PubMed ID: 1584347
[TBL] [Abstract][Full Text] [Related]
17. Cellular and functional characterization of immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes reveals their up-regulated synthesis of biologically active TGF-beta.
Gomez GG; Kruse CA
J Immunother; 2007 Apr; 30(3):261-73. PubMed ID: 17414317
[TBL] [Abstract][Full Text] [Related]
18. The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1.
Bergmann L; Schui DK; Brieger J; Weidmann E; Mitrou PS; Hoelzer D
Exp Hematol; 1995 Dec; 23(14):1574-80. PubMed ID: 8542949
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta.
Newcom SR; Tagra KK; Kadin ME
Am J Pathol; 1992 Mar; 140(3):709-18. PubMed ID: 1312308
[TBL] [Abstract][Full Text] [Related]
20. Endogenous expression of transforming growth factor beta1 inhibits growth and tumorigenicity and enhances Fas-mediated apoptosis in a murine high-grade glioma model.
Ashley DM; Kong FM; Bigner DD; Hale LP
Cancer Res; 1998 Jan; 58(2):302-9. PubMed ID: 9443409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
